What are your top takeaways in Hematologic Malignancies from ASCO 2024?

The top three would be

1. IMROZ
2. DREAMM-8
3. BENEFIT

I would say I’m a DREAMMer :)
The DREAMM-8 (BPd vs PVd) results were truly impressive.

Both DREAMM-7 and DREAMM-8 trials illustrate how well Belantamab Mafodotin pairs with proteasome inhibitors and immunomodulatory agents. In addition, for patients with relapsed refractory myeloma, having been lenali...

Always an exciting conference for myeloma and this year was no exception.

1. IMROZ study: The management of newly diagnosed multiple myeloma (NDMM) has evolved significantly over the past few years. One of the first clinical assessments in planning treatment is determining eligibility for autologous ...

For multiple myeloma, my "top 3" presentations were:

1. BENEFIT/IFM 2020-05 study (Leleu et al., #7501) - Isa-VRd with once-weekly bortezomib beat Isa-Rd in transplant-ineligible patients with regard to MRD negativity (PFS results still pending). This study is getting overshadowed by IMROZ, which is un...